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For decades, elevated plasma cortisol concentrations in criticaly ill patients were exclusively ascribed to 
a stimulated hypothalamus-pituitary-adrenal axis with increased circulating adrenocorticotropic hormone 
(ACTH) inferred to several-fold increase adrenal cortisol synthesis. However, ‘ACTH-cortisol 
dissociation’ has been reported during critical illness, referring to low circulating ACTH coinciding with 
elevated circulating cortisol. 
It was recently shown that metabolism of cortisol is significantly reduced in critically ill patients explained 
by a suppression of the activity and expression of cortisol metabolizing enzymes in kidney and liver. 
This reduced cortisol breakdown determines hypercortisolemia, much more than increased cortisol 
production, in the critically ill. Although the low plasma ACTH concentrations, evoked by the elevated 
plasma cortisol via feedback inhibition, are part of this adaptation, they may negatively affect 
adrenocortical structure and function in the prolonged phase of critical illness. These new insights have 
implications for diagnosis and treatment of adrenal insufficiency in critically ill patients. 
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1. INTRODUCTION 
Critical illness is defined as any condition that requires support of failing vital organ functions without 
which death would ensue.  The human body aims to maintain homeostasis which, after a challenge, 
should be re-established by means of various physiological and behavioral responses (Chrousos, 
2009), together summarized in the term ‘the stress response’. These adaptations comprise an activation 
of the hypothalamus-pituitary-adrenal (HPA) axis which brings about a rise in plasma cortisol 
concentration. Elevated plasma cortisol mediates vital endocrine and metabolic effects such as fostering 
energy provision, dampening inflammation and ensuring hemodynamic homeostasis via fluid retention 
and sensitization to catecholamines. As critical illness represents a major threat to the equilibrium of the 
internal environment of the human body, the capacity to cope with life-threatening internal and external 
stressors determines the odds of survival of critical illness.  
Most critically ill patients exhibit elevated plasma cortisol concentrations proportionately to the severity 
of illness (Widmer et al., 2005). For decades, intensivists ascribed this hypercortisolemia exclusively to 
the degree of activation of the HPA axis. However, low instead of high plasma adrenocorticotropic 
hormone (ACTH) concentrations were reported in critically ill patients in the presence of elevated 
circulating cortisol levels (Vermes et al., 1995). This was then addressed as ‘ACTH-cortisol 
dissociation’, quite an unexpected observation given the state of sustained and severe stress in these 
patients. Furthermore, both high and low plasma cortisol levels have been associated with increased 
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risk of death during critical illness (Cooper and Stewart, 2003,Rothwell and Lawler, 1995). In this context 
the term ‘relative adrenal insufficiency’ emerged (also called ‘critical illness-related corticosteroid 
insufficiency’ (CIRCI)), describing the situation in which plasma cortisol concentrations, although much 
higher than during health, may not suffice to cope with the level of stress (Annane et al., 2000). 
Currently, appropriate diagnostic criteria for relative adrenal failure remain highly debated, as the 
underlying mechanisms remain unclear. Moreover, due to conflicting results of studies investigating the 
impact of “stress doses” of hydrocortisone, there is no consensus on whether or not patients suffering 
from this disorder should receive exogenous glucocorticoid therapy (Annane et al., 2002,Sprung et al., 
2008).   
Recent new insights reshaped the comprehension of the HPA axis response to critical illness and its 
effects on the adrenal gland. These insights could clarify some of the controversy currently present in 
the literature. This review article summarizes the content of a lecture by G. Van den Berghe at the 
Adrenal 2014 Conference in Chicago. 
 
2. THE CONTROL OF THE HPA AXIS DURING HEALTH 
When the human brain senses stressful events, it signals the paraventricular nucleus (PVN) of the 
hypothalamus to release corticotropin-releasing hormone (CRH) and arginine vasopressin, which 
activate the anterior pituitary gland to release ACTH that drives adrenal cortisol synthesis and secretion. 
Concomitantly with this HPA axis activation, the sympathetic nervous system is activated. Cortisol in 
turn evokes feed-back inhibition via binding to both glucocorticoid receptors and mineralocorticoid 
receptors at the level of the hypothalamus and the pituitary to fine-tune its own release (Keller-Wood 
and Dallman, 1984).   
 To maintain daily homeostasis, the PVN also receives information from the hypothalamic 
suprachiasmatic nucleus, which is needed to bring about the circadian pattern of HPA axis activity 
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(Walker et al., 2010), with the highest levels of ACTH and cortisol secretion present in the morning, in 
anticipation of wakening, and the lowest levels present during sleep. The tightly coupled release of 
ACTH and cortisol also follows an ultradian rhythm, with rapid secretory pulses superimposed on a 
nonpulsatile release. 
When homeostasis is threatened, additional secretion of ACTH and cortisol is required, to prepare for 
the fight or flight reaction. As such, during acute stress, elevated plasma ACTH concentrations seem to 
be the main driver of glucocorticoid production, both by an immediate effect as well as by increasing the 
steroidogenic capacity of the adrenal gland. In addition, hypertrophy and hyperplasia of the adrenal 
cortex together with hypervascularization of the adrenal glands have been observed in response to 
ACTH-stimulation (Ehrhart-Bornstein et al., 1998).   
 
3. HPA AXIS REGULATION DURING CRITICAL ILLNESS 
Within this traditional concept of the stress response, also the hypercortisolism of critical illness, a 
condition of sustained and severe stress, is assumed to be brought about mainly by increased release 
of ACTH from the anterior pituitary into the systemic circulation. However, published data on the levels 
of plasma ACTH during critical illness are scarce. Most of the available studies quantified plasma ACTH 
concentrations at one single time point, and often no comparison with healthy control subjects was done 
(Annane et al., 2006,Drucker and Shandling, 1985,Michalaki et al., 2010,Roth-Isigkeit and Schmucker, 
1997). In contrast, Vermes et al. reported daily plasma ACTH concentrations measured in trauma 
patients or patients with sepsis, in comparison with healthy controls, and more recently, Boonen et al. 
did the same in a more heterogeneous and severely ill ICU population (Boonen et al., 2013,Vermes et 
al., 1995). Both studies reported plasma ACTH concentrations falling below the healthy control values 
during the first week of critical illness, whereas plasma cortisol concentrations remained high (Fig. 1). 
This phenomenon of low ACTH together with high cortisol, has been called ‘ACTH cortisol dissociation’.  
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A dissociation of ACTH and cortisol could theoretically be brought about by increased ACTH sensitivity 
or alternative stimuli driving adrenocortical cortisol production, such as neuropetides, cytokines or 
adipokines (Bornstein et al., 2008). Alternatively, hypercortisolism could be explained by reduced 
cortisol metabolism. Plasma cortisol that is elevated via reduced breakdown might then suppress ACTH 
secretion via negative feedback inhibition. This hypothesis was recently investigated (Boonen et al., 
2013,Boonen et al., 2014b). 
 
3.1   CORTISOL PRODUCTION AND METABOLISM 
The rate of cortisol production and the plasma clearance of cortisol in critically ill patients were 
quantified, in relation to circulating ACTH and cortisol plasma concentrations, via 4 clinical studies in 
heterogeneous populations of critically ill patients compared with a matched population of control 
subjects (Boonen et al., 2013). First cortisol production rate was measured via a stable isotope 
(deuterated cortisol) infusion technique. Remarkably, cortisol production turned out to be only slightly 
elevated, not even double that of healthy subjects, and this was only the case for critically ill patients 
suffering from the systemic inflammatory response syndrome (SIRS) while cortisol production was 
unchanged in critically ill patients without SIRS. Yet, plasma free and total cortisol concentrations, on 
the other hand, were several-fold higher in all patients. Further exploring this increased production, the 
main pro-inflammatory cytokines TNF-α and IL-6, known to be substantially increased in patients as 
compared with controls, were positively correlated with cortisol production. This suggests that cytokines 
could play a causal role as an ACTH-independent mechanism driving the moderately increased cortisol 
production in the critically ill. It is interesting to note that the cortisol production rates observed during 
these life-threatening critical illnesses in patients depending on mechanical ventilation and other vital 
organ support were in the same ranges as those reported in old studies for patients suffering from mild 
infections or during a COPD exacerbation (Cornil et al., 1968,Cornil et al., 1975). 
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Furthermore, the stable isotope technique in the study of critically ill patients allowed to quantify 
clearance of plasma cortisol. In all patients this was found to be suppressed to less than half, regardless 
of the inflammation status. Also the plasma clearance of a bolus injection of a therapeutic dose of 100 
mg hydrocortisone was found to be 60% lower than that in healthy subjects, and, in patients, the cortisol 
half-life was found to be a median 5-fold longer. This suppressed cortisol breakdown was further 
explored by investigating cortisol metabolizing enzyme activity and tissue expression levels. In the 
human body, cortisol is mainly broken down via 5α-reductase and 5β-reductase (A-ring reductases) in 
liver tissue and adipose tissue, and via 11β-hydroxysteroid dehydrogenase (11β-HSD) type 2 in kidney 
(Fig. 2). Furthermore, 11β-HSD type 1 can reconvert cortisol from cortisone predominantly in liver and 
adipose tissue. The A-ring reductase expression and activity in liver and the 11β-HSD2 activity were 
found to be significantly diminished in critically patients, as quantified by tracer kinetics, urinary steroid 
ratios and assessment of human liver and adipose-biopsy samples. 
The suppressed cortisol breakdown during critical illness could be interpreted as an adaptive 
mechanism to reduce energy consumption in times of increased cortisol need and a reduced energy 
availability. Indeed, if stress increases the need for cortisol in vital organs and tissues, it seems the most 
economic and logical first event to stop breaking it down in times of low energy availability. Remarkably, 
the reduced plasma cortisol clearance was observed in all critically ill patients, regardless of type, 
severity of illness, ICU stay or prognosis. This suggested that reduced cortisol metabolism could be a 
key component of the acute or semi-acute stress response to critical illness, together with ongoing 
normal or mildly elevated cortisol production. 
The finding that the elevated plasma cortisol concentrations in critically ill patients are determined to a 
large extent by reduced cortisol metabolism could elucidate the observed low circulating ACTH 
concentrations. Indeed, negative feedback inhibition at the level of the hypothalamus and the pituitary 
gland is theoretically responsible for these low plasma ACTH concentrations. However, previous studies 
that investigated the interaction between ACTH and cortisol during critical illness were based on only 
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one time point and did not take into account the pulsatile secretory pattern of both ACTH and cortisol. 
Recently, the dynamics of cortisol and ACTH during critical illness were assesed with mathematical 
analyses applied to repeated sampling time series of plasma concentrations in critically ill patients and 
in healthy volunteers (Boonen et al., 2014b). Nocturnal hormonal secretory profiles were created by 
deconvolution analysis, which took into account the previously documented prolonged cortisol half-life, 
and which allowed to quantify pulsatile and non-pulsatile secretion of cortisol and ACTH (Veldhuis et al., 
2008). The study revealed that nocturnal ACTH as well as cortisol pulsatile secretion rates were 
reduced during critical illness, which again speaks against the generally accepted hypothesis of a 
stimulated HPA axis in response to critical illness. In addition, the secretion of cortisol in response to 
ACTH was found to be unaltered. This preserved dose-response between ACTH and cortisol also 
suggested that the term ‘ACTH-cortisol dissociation’ may not be entirely correct, given the fact that the 
association between ACTH and cortisol secretion remained present.  In addition, these findings are not 
in favor of an increased adrenocortical sensitivity to ACTH as an explanation for the high plasma cortisol 
concentrations in critically ill patients. Also a high asynchrony and irregularity between the cortisol and 
ACTH time series further supported the presence of other ACTH-independent mechanisms contributing 
to hypercortisolemia of the critically ill. Interestingly, whereas IL-6 and TNFα correlated positively with 
cortisol production in the previous study, both cytokines, although markedly increased, now correlated 
negatively with cortisol secretion. This reduces the likelihood that cytokines stimulate cortisol production 
during critical illness. Ideally 24h cortisol production should be assessed, yet this remains a practical 
challenge in the ICU-setting. However, bringing together the results of the two clinical studies mentioned 
above, it appears that the overall 24h cortisol production rate in critical ill patients is not, or only slightly, 
higher than in healthy control subjects.   
Although the negative feedback inhibition exerted by cortisol on the anterior pituitary and the 
hypothalamus would expectedly evoke even lower plasma ACTH concentrations than those observed, 
severe neurogenic stress and large amounts of CRH can partially overcome this feedback inhibition 
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(Watts, 2005). A schematic overview of these and other known regulators of the HPA axis is given in 
Figure 3. 
 
3.2    THE POTENTIAL ROLE OF BILE ACIDS 
In theory, hypoperfusion of organs responsible for cortisol breakdown could explain the reduced cortisol 
metabolism. However, this did not explain the findings mentioned above (Boonen et al., 2013). Given 
the fact that conjugated as well as unconjugated bile acids are known suppressors of all cortisol 
metabolizing enzymes (McNeilly et al., 2010,Stauffer et al., 2002), and the earlier observation of 
elevated bile acid concentrations in the blood of critically ill patients (Vanwijngaerden et al., 2011), 
circulating bile acids were quantified in the studied patients. A strong inverse correlation was observed 
between circulating bile acid levels and the A-ring reductase gene and protein expression levels, 
suggesting that elevated levels of bile acids may reduce cortisol metabolism in critically ill patients.  
High plasma levels of bile acids during critical illness could be part of the adaptive stress response. 
Indeed, whereas export of bile acids into the bile consumes a lot of energy as it is export against a 
concentration gradient, the reversed transport of conjugated bile acids towards the blood instead of into 
the bile canaliculi inferentially lowers energy consumption (Vanwijngaerden et al., 2011). Other possible 
benefits could relate to the effects of bile acids on brown adipose tissue and its link with insulin 
sensitivity (Watanabe et al., 2006).  
The interplay between the HPA axis and bile acids in other conditions and diseases is investigated 
intensively. For instance, the farnesoid X receptor (FXR), a nuclear receptor, was shown to be activated 
by bile acids and is therefore known as the bile acid sensor. During critical illness, increased serum bile 
acid levels together with suppressed FXR have been reported, suggesting, at least in part, loss of bile 
acid sensing and ongoing bile acid production (Vanwijngaerden et al., 2011). Furthermore, FXR has 
shown to upregulate key steroidogenic enzymes (Chao et al., 2010,Xing et al., 2009). In addition low 
plasma ACTH and high plasma cortisol levels have been documented during cholestasis (Zietz et al., 
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2001). Also, it has been shown in a bile-ligated model of cholestasis in the rat, that the HPA axis is 
suppressed at the level of ACTH as well as CRH expression (Quinn et al., 2012). The association 
between increased bile acids and reduced cortisol metabolizing enzyme expression during critical 
illness is only suggestive of a possible causal role and should be further investigated in experimental 
models.  
 
3.3     CONSEQUENCES OF REDUCED CORTISOL BREAKDOWN DURING CRITICAL 
ILLNESS 
Where reduced cortisol metabolism initially could be interpreted as an ‘economic’ way to maintain 
cortisol levels during critical illness, the ensuing low ACTH concentrations could, when sustained, 
negatively affect adrenal structure and function. Indeed, ACTH exerts different important functions on 
the adrenal gland to ensure immediate cortisol production from cholesterol in the adrenal gland. Within 
minutes after onset of acute stress, ACTH activates its receptor, the melanocortin 2 receptor (MC2R) on 
the adrenal cortex which causes the release of cholesterol from the lipid droplets and increases the 
expression of the steroidogenic acute regulatory protein (STAR), transporting cholesterol to the inner 
membrane of the mitochondria (Simpson and Waterman, 1983). Furthermore, the long-term impact of 
ACTH on the adrenal cortex involves increased transcription of genes important for cholesterol uptake 
(scavenger-receptor class B, member 1 (SCARB1), low-density lipoprotein receptor (LDLR)), for 
cholesterol synthesis (3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR)) and for steroidogenesis 
(STAR and CYP11A1) as such enhancing the synthetic capacity of the cells (Lehoux et al., 
1989,Lehoux et al., 1998,Liu et al., 2000,Simpson and Waterman, 1983,Stocco and Clark, 1996). In 
addition, ACTH has a direct stimulatory effect on the expression of its own receptor (MC2R) which 
amplifies the adrenal responsiveness to ACTH (Lebrethon et al., 1994). Finally, ACTH ensures adrenal 
gland structure and growth. Considering the extensive acute and chronic impact of ACTH on the adrenal 
cortex, persistently low plasma ACTH concentrations could thus also profoundly affect the adrenal 
cortex. Indeed, lack of ACTH, as occurs in pro-opiomelanocortin(POMC) knock-out mice, causes 
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atrophic and hypofunctional adrenal glands (Coll et al., 2004,Karpac et al., 2008), and POMC-deficiency 
in human patients is characterized by loss of adrenocortical zonational structure, adrenocortical lipid 
depletion, reduced ACTH signaling and adrenal atrophy/failure (Krude and Gruters, 2000). 
In the light of this knowledge, the impact of duration of critical illness on the adrenal cortex was recently 
studied. Adrenal glands were harvested immediately postmortem from patients who died in the ICU after 
a long (>7 days) or short (≤7 days) ICU-stay and compared with ‘controls’ who died suddenly out-of-
hospital (Boonen et al., 2014a). In long ICU-stay patients, but not in the short-stay patients or the 
controls, loss of zonational structure, severe cholesterol-ester depletion and substantially reduced 
mRNA expression of the ACTH-regulated genes MC2R, SCARB1, STAR and CYP11A1 were observed. 
These findings again argue against the presence of increased adrenocortical sensitivity to ACTH as an 
explanation of high plasma cortisol concentrations during critical illness, since ACTH-regulated genes 
were not upregulated. Furthermore, these changes are comparable with the changes observed in 
POMC-deficient mice. Therefore, a significant loss of ACTH signaling in the adrenal cortex may have 
important negative consequences for the integrity and function of the adrenal gland during the 
prolonged course of critical illness.  
 
4. DIAGNOSTIC AND THERAPEUTIC IMPLICATIONS 
The terms ‘relative adrenal insufficiency’ or ‘critical illness related corticosteroid insufficiency’ (CIRCI) 
have been used to identify the condition in which plasma cortisol concentrations are elevated but the 
degree of hypercortisolism does not suffice to cope with the level of stress during critical illness, which 
may unfavorably affect patients’ outcome. Despite the extensively discussed concept of CIRCI, the 
exact diagnostic criteria and the therapeutic options have not been agreed upon. Several diagnostic 
criteria have been suggested. As the current concept of relative adrenal insufficiency during critical 
illness refers to an adrenal gland that, though maximally stimulated by ACTH, cannot produce enough 
cortisol to meet the high need, a low rise in plasma cortisol concentrations to an injection of ACTH 
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would be indicative of this condition. Annane et al. suggested that relative adrenal insufficiency is likely 
present when the incremental rise in plasma cortisol concentration after 250 µg ACTH injection is less 
than 9 µg/dl (Annane et al., 2006). Others have suggested that a random plasma cortisol less than 10 
µg/dl is also indicative of CIRCI. However, given that cortisol is secreted in pulses, single 
measurements of total plasma cortisol could be problematic to judge the adequacy of the cortisol 
production rate during critical illness.  
However, also the usability of an ACTH stimulation test to diagnose relative adrenal failure during critical 
illness could be questioned, based on the recent new insights. It was shown that the rise in plasma 
cortisol in response to an ACTH stimulation test during critical illness was positively correlated both with 
cortisol production rate and with clearance of plasma cortisol (Boonen et al., 2013). These findings 
suggest that a suppression of cortisol plasma clearance could explain a reduced cortisol response to an 
ACTH stimulation test, because it may just reflect negative feedback inhibition exerted by cortisol. A 
similar phenomenon occurs in patients treated with exogenous glucocorticoids, who also exhibit a lower 
response to an ACTH stimulation test (Sacre et al., 2013).  Furthermore, a dose of 250µg of ACTH 
used in an ACTH stimulation test may lead to supra-physiologic plasma ACTH levels and could hereby 
overcome any ACTH resistance. Alternatively, a 1 µg stimulation dose has been suggested.However, 
this has not been widely studied during critical illness and reported results have been conflicting. 
Recently, it was shown that in 5α-reductase knock-out mice, a degree of adrenal insufficiency develops 
(Livingstone et al., 2014). Whereas plasma corticosterone, the cortisol equivalent in mice, and plasma 
ACTH concentrations were normal in these knock-out mice, clearance of plasma corticosterone and the 
corticosterone response to an ACTH injection and to a physicial stressor were lower than in wild-type 
mice. These findings support that reduced cortisol metabolism, with time, may contribute to the 
development of adrenal failure. Also, other investigators have not all been able to replicate the original 
observations by Annane et al. and the newest guidelines no longer advise to utilize the ACTH 
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stimulation test to guide treatment with hydrocortisone (Dellinger et al., 2008), currently explaining the 
lack of consensus on how to diagnose adrenal failure in the ICU.  
Patients with presumed relative adrenal failure during critical illness, and with signs of shock, currently 
are being treated with high doses of hydrocortisone in order to increase the responsiveness to treatment 
with vasopressors and fluids (Dellinger et al., 2013). However, exposure of skeletal muscle tissue to 
such high doses of hydrocorticone may cause increased risk of myopathy, aggravated muscle wasting, 
and extended ICU dependency (Hermans et al., 2007,Hermans et al., 2008). Particularly in the 
presence of suppressed breakdown of cortisol, as shown during critical illness, these side effects may 
be substantial and could abrogate any potential benefit of the shock reversal with high dose 
hydrocortisone.  Furthermore, whether or not (and with which doses) patients with relative adrenal 
insufficiency should  receive exogenous glucocorticoid therapy, remains unclear, as the results from 
large randomized intervention studies have generated conflicting results (Annane et al., 2002,Sprung et 
al., 2008).   
 
5. CONCLUSIONS 
Recent studies have shown that cortisol metabolism is significantly and robustly reduced in critically ill 
patients, due to suppressed activity and expression of enzymes responsible for cortisol breakdown in 
vital organs such as liver and kidney. This reduced cortisol breakdown, rather than a several-fold 
increased cortisol production rate, appears to determine the high circulating levels of cortisol during 
critical illness. This could represent a highly economic way to adapt to stress, although the ensuing 
suppressed circulating levels of ACTH with time could negatively affect adrenal structure and function.  
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FIGURE LEGENDS 
Figure 1 - ACTH cortisol dissociation 
Shown are mean morning values for plasma cortisol (Panel A) and ACTH (Panel B) concentrations in 
patients during the first week of critical illness. The error bars indicate standard errors of the mean. The 
shaded area represents the interquartile range of values in healthy matched control subjects. From ICU 
day 1 to day 7, plasma cortisol concentrations in patients remained elevated (P=0.01), and plasma 
ACTH concentrations remained lower than in healthy controls (P<0.001). (Figure was drafted from 
original data from Boonen et al, 2013, with permission. © Massachusetts Medical Society.) 
(2-column fitting image) 
Figure 2 - Cortisol metabolism in the human body 
In the kidney, cortisol is metabolized by 11β-hydroxysteroid dehydrogenase (11β-HSD) type 2 
generating cortisone. Cortisol and cortisone are mainly broken down via A-ring reductases, 5α-
reductase and 5β-reductase, in the liver to generate 5α- and 5β-tetrahydrocortisol.  
(2-column fitting image) 
Figure 3 - Simplified overview of regulation of the hypothalamus-pituitary-adrenal axis and 
cortisol metabolism during critical illness 
↑, elevated plasma concentrations; ↓, decreased plasma concentrations; ?, uncertain; +, stimulates; -, 
inhibits; PVN, paraventricular nucleus; AVP, arginine vasopressine; ACTH, adrenocorticotropic 
hormone; CBG, corticosteroid-binding globulin; PG, prostaglandins; CCK, cholecystokinin; GABA, 
gamma-aminobutyric acid; VIP, vasoactive intestinal peptide; NO, nitric oxide; NPY, neuropetide Y; 
PACAP, pituitary adenylate cyclase-activating peptide; ANP, atrial natriuretic peptide. 
(2-column fitting image) 
 
 19 
FIGURES 
 
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 
 20 
Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
